Skip to main content Accessibility help

Screening strategies to identify new chemical diversity for drug development to treat kinetoplastid infections

  • ROB DON (a1) and JEAN-ROBERT IOSET (a1)


The Drugs for Neglected Diseases initiative (DNDi) has defined and implemented an early discovery strategy over the last few years, in fitting with its virtual R&D business model. This strategy relies on a medium- to high-throughput phenotypic assay platform to expedite the screening of compound libraries accessed through its collaborations with partners from the pharmaceutical industry. We review the pragmatic approaches used to select compound libraries for screening against kinetoplastids, taking into account screening capacity. The advantages, limitations and current achievements in identifying new quality series for further development into preclinical candidates are critically discussed, together with attractive new approaches currently under investigation.


Corresponding author

*Corresponding author: Drugs for Neglected Diseases initiative, 15 Chemin Louis-Dunant, 1202 Geneva, Switzerland. Tel: +41 (0) 22 906 92 65. Fax: +41 (0) 22 906 92 31. E-mail:


Hide All
Bell, A. S., Bradley, J., Everett, J. R., Knight, M., Loesel, J., Mathias, J., McLoughlin, D., Mills, J., Sharp, R. E., Williams, C. and Wood, T. P. (2013). Plate-based diversity subset screening: an efficient paradigm for high throughput screening of a large screening file. Molecular Diversity 17, 319335. doi: 10.1007/s11030-013-9438-x.
Castillo, E. A., Dea-Ayuela, M., Bolas-Fernandez, F., Rangel, M. E. and Gonzalez-Rosende, M. (2010). The kinetoplastid chemotherapy revisited: current drugs, recent advances and future perspectives. Current Medicinal Chemistry 17, 40274051.
Chawla, B. and Madhubala, R. (2010). Drug target in Leishmania. Journal of Parasitology Disease 34, 113.
Das, A., Dasgupta, A., Sengupta, T. and Majumder, H. K. (2004). Topoisomerases of kinetoplastid parasites as potential chemotherapeutic targets. Trends in Parasitology, 20, 381387.
De Rycker, M., Hallyburton, I., Thomas, J., Campbell, L., Wyllie, S., Joshi, D., Cameron, S., Gilbert, I. H., Wyatt, P. G., Frearson, J. A., Fairlamb, A. H. and Gray, D. W. (2013). Comparison of a high-throughput high-content intracellular Leishmania donovani assay with an axenic amastigote assay. Antimicrobial Agents and Chemotherapy 57, 29132922. doi: 10.1128/AAC.02398-12.
Feher, M. and Schmidt, J. M. (2003). Property distributions: differences between drugs, natural products, and molecules from combinatorial chemistry. Journal of Chemical Information and Modeling 43, 218227.
Frearson, J. A., Brand, S., McElroy, S. P., Cleghorn, L. A., Smid, O., Stojanovski, L., Price, H. P., Guther, M. L., Torrie, L. S., Robinson, D. A., Hallyburton, I., Mpamhanga, C. P., Brannigan, J. A., Wilkinson, A. J., Hodgkinson, M., Hui, R., Qiu, W., Raimi, O. G., van Aalten, D. M., Brenk, R., Gilbert, I. H., Read, K. D., Fairlamb, A. H., Ferguson, M. A., Smith, D. F. and Wyatt, P. G. (2010). N-myristoyltransferase inhibitors as new leads to treat sleeping sickness. Nature 464, 728732. doi: 10.1038/nature08893.
Frearson, J. A., Wyatt, P. G., Gilbert, I. H. and Fairlamb, A. H. (2007). Target assessment for antiparasitic drug discovery. Trends in Parasitology 23, 589595.
Gamo, F. J., Sanz, L. M., Vidal, J., de Cozar, C., Alvarez, E., Lavandera, J. L., Vanderwall, D. E., Green, D. V., Kumar, V., Hasan, S., Brown, J. R., Peishoff, C. E., Cardon, L. R. and Garcia-Bustos, J. F. (2010). Thousands of chemical starting points for antimalarial lead identification. Nature 465, 305310. doi: 10.1038/nature09107.
Ioset, J.-R. and Chang, S. (2011). Drugs for neglected diseases initiative model of drug development for neglected diseases: current status and future challenges. Future Medicinal Chemistry 1, 13611371. doi: 10.4155/fmc.11.102.
Jamal, S. and Periwal, V. (2013). Open source drug discovery consortium, Scaria V. Predictive modeling of anti-malarial molecules inhibiting apicoplast formation. BMC Bioinformatics 15, 5562. 14:55. doi: 10.1186/1471-2105-14-55.
Keller, T. H., Shi, P. Y. and Wang, Q. Y. (2011). Anti-infectives: can cellular screening deliver? Current Opinion in Chemical Biology 15, 529533. doi: 10.1016/j.cbpa.2011.06.007.
Kima, P. E. (2007). The amastigote forms of Leishmania are experts at exploiting host cell processes to establish infection and persist. International Journal for Parasitology 37, 10871096.
Kogej, T., Blomberg, N., Greasley, P. J., Mundt, S., Vainio, M. J., Schamberger, J., Schmidt, G. and Hüser, J. (2013). Big pharma screening collections: more of the same or unique libraries? The AstraZeneca-Bayer Pharma AG case. Drug Discovery Today
Lang, T., Hellio, R., Kaye, P. M. and Antoine, J. C. (1994). Leishmania donovani-infected macrophages: characterization of the parasitophorous vacuole and potential role of this organelle in antigen presentation. Journal of Cell Science 107, 21372150.
McKerrow, J. H., Rosenthal, P. J., Swenerton, R. and Doyle, P. (2008). Development of protease inhibitors for protozoan infections. Current Opinion in Infectious Diseases 21, 668672. doi: 10.1097/QCO.0b013e328315cca9.
Payne, D. J., Gwynn, M. N., Holmes, D. J., and Pompliano, D. L. (2007). Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nature Reviews Drug Discovery 6, 2940.
Periwal, V. and Kishtapuram, S. (2012). Open Source Drug Discovery Consortium, Scaria V. Computational models for in-vitro anti-tubercular activity of molecules based on high-throughput chemical biology screening datasets. BMC Pharmacology 31, 17. 12:1. doi: 10.1186/1471-2210-12-1.
Pescher, P., Blisnick, T., Bastin, P. and Spath, G. F. (2011). Quantitative proteome profiling informs on phenotypic traits that adapt Leishmania donovani for axenic and intracellular proliferation. Cell Microbiology 13, 978991. doi: 10.1111/j.1462-5822.2011.01593.x.
Renslo, A. R. and McKerrow, J. H. (2006). Drug discovery and development for neglected parasitic diseases. Nature Chemical Biology 2, 701710.
Sams-Dodd, F. (2005). Target-based drug discovery: is something wrong? Drug Discovery Today 10, 139147.
Siqueira-Neto, J. L., Moon, S., Jang, J., Yang, G., Lee, C., Moon, H. K., Chatelain, E., Genovesio, A., Cechetto, J. and Freitas-Junior, L. H. (2012). An image-based high-content screening assay for compounds targeting intracellular Leishmania donovani amastigotes in human macrophages. PLoS Neglected Tropical Diseases 6, e1671. doi: 10.1371/journal.pntd.0001671.
Sykes, M. L. and Avery, V. M. (2009). Development of an Alamar Blue viability assay in 384-well format for high throughput whole cell screening of Trypanosoma brucei brucei bloodstream form strain 427. American Journal of Tropical Medicine and Hygiene 81, 665674. doi: 10.4269/ajtmh.2009.09-0015.
Wyatt, P. G., Gilbert, I. H., Read, K. D. and Fairlamb, A. H. (2011). Target validation: linking target and chemical properties to desired product profile. Current Topics in Medicinal Chemistry 11, 12751283.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

  • ISSN: 0031-1820
  • EISSN: 1469-8161
  • URL: /core/journals/parasitology
Please enter your name
Please enter a valid email address
Who would you like to send this to? *



Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed